The estimated Net Worth of Shawn Oconnor is at least $879 Thousand dollars as of 23 November 2020. Shawn Oconnor owns over 5,500 units of Simulations Plus stock worth over $209,361 and over the last 5 years Shawn sold SLP stock worth over $669,902.
Shawn has made over 3 trades of the Simulations Plus stock since 2019, according to the Form 4 filled with the SEC. Most recently Shawn sold 6,381 units of SLP stock worth $360,527 on 30 November 2020.
The largest trade Shawn's ever made was exercising 20,000 units of Simulations Plus stock on 20 November 2019 worth over $475,000. On average, Shawn trades about 4,554 units every 54 days since 2019. As of 23 November 2020 Shawn still owns at least 6,381 units of Simulations Plus stock.
You can see the complete history of Shawn Oconnor stock trades at the bottom of the page.
Shawn's mailing address filed with the SEC is 42505, 10th Street West, Lancaster, California, 93534, United States.
Over the last 21 years, insiders at Simulations Plus have traded over $70,055,940 worth of Simulations Plus stock and bought 24,000 units worth $1,395,840 . The most active insiders traders include Walter Swoltosz Virginia E ..., Walter S Woltosz, and Momoko A Beran. On average, Simulations Plus executives and independent directors trade stock every 37 days with the average trade being worth of $571,025. The most recent stock trade was executed by Jill Fiedler Kelly on 9 September 2024, trading 2,250 units of SLP stock currently worth $21,848.
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
Simulations Plus executives and other stock owners filed with the SEC include: